Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 1,307 trials

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Burn Patients: Antibiotic Use Before Surgery

We are studying whether giving antibiotics before skin graft surgery helps reduce infections and complications in burn patients. This research may provide insights into improving recovery and hospital stays.

Burn Injury>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Candidiasis Treatment: Mecloderm® Cream Study

We are comparing a new cream to standard treatments and a placebo for patients with moderate to severe skin candidiasis. The goal is to see which option works best for reducing inflammation and discomfort.

Skin and Nail Candidiasis>2 yearsConfirmation phase (III)Dermatology

Chronic Immune Thrombocytopenia: Mezagitamab Injection

We are studying a new injection, mezagitamab, for adults with chronic immune thrombocytopenia to see if it can improve platelet counts and reduce symptoms compared to a placebo.

Primary Immune Thrombocytopenia6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematology

BCG Vaccination: Understanding Immune Response

We are studying how pre-vaccination immune status affects the response to the BCG vaccine. This research may help improve vaccination strategies by identifying key immune factors.

Healthy Participants>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

New Treatment for Primary CNS Lymphoma: Optimizing MATRix

We are studying a modified treatment approach for patients with newly diagnosed primary CNS lymphoma to see if it improves survival and quality of life compared to standard therapy. This trial aims to find a safer and effective way to induce remission before further treatment.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Wart Treatment: 2LVERU® JUNIOR and 2LVERU®

We are studying whether two new treatments can help people with warts get rid of them more effectively than a placebo. The trial will also look at pain levels and safety during treatment.

Warts>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesDermatologyInfectious Diseases

Compulsive Sexual Behavior Disorder: Medication Study

We are comparing the effects of escitalopram, naltrexone, and their combination on symptoms of compulsive sexual behavior. This study aims to understand how these treatments may improve daily functioning and emotional well-being.

Compulsive Sexual Behavior3-6 monthsConfirmation phase (III)Investigational MedicinesPsychiatry

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure Risk: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin can lower the risk of heart failure and cardiovascular death in people at increased risk. This trial compares this combination to dapagliflozin alone.

Heart Failure Signs and Symptoms>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyInternal Medicine

Acute Myeloid Leukemia: Low Intensity Therapy Study

We are exploring whether a gentler treatment approach helps patients with relapse or refractory acute myeloid leukemia live longer and feel better compared to stronger therapies.

Acute Myeloid LeukemiaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Familial Hypercholesterolemia: Inclisiran vs. Alirocumab

We are comparing two new treatments, inclisiran and alirocumab, to standard therapy for children with heterozygous familial hypercholesterolemia. The goal is to see which treatment better lowers cholesterol levels and improves quality of life.

Heterozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyEndocrinology

Allergy Vaccine for Grass and Cupressaceae Allergies

We are studying a new vaccine for people with allergies to grasses and cupressaceae, including those with mild to moderate asthma. The trial aims to see if this vaccine is more effective and safe than a placebo during pollen season.

Pollen AllergyAllergic RhinitisAllergic AsthmaConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Inclisiran for Children with High Cholesterol

We are studying the safety and effectiveness of inclisiran in children aged 2 to under 12 years with homozygous familial hypercholesterolemia. The goal is to see if it can lower their cholesterol levels compared to a placebo.

Homozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Thyroid Cancer Treatment: Radioiodine Strategies

We are comparing two treatment strategies for intermediate-risk differentiated thyroid cancer patients to see which is more effective. This study will also evaluate patient quality of life and side effects over time.

Thyroid Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Hepatoblastoma and Hepatocarcinoma: Personalized Treatment Study

We are investigating new ways to tailor treatments for children with liver cancer to improve effectiveness and reduce side effects. This study also aims to better understand the genetic features of these tumors.

Hepatoblastoma and Liver CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease: CTX001 Treatment

We are studying a new gene therapy using modified stem cells for adolescents and adults with transfusion-dependent β-thalassemia or severe sickle cell disease. The goal is to evaluate its effectiveness and safety in improving their condition.

Transfusion-dependent β-thalassemiaSevere sickle cell disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematology

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology